248 related articles for article (PubMed ID: 37975798)
1. Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis.
Saini A; Chawla PA
Eur J Neurol; 2024 Feb; 31(2):e16140. PubMed ID: 37975798
[TBL] [Abstract][Full Text] [Related]
2. Tofersen: First Approval.
Blair HA
Drugs; 2023 Jul; 83(11):1039-1043. PubMed ID: 37316681
[TBL] [Abstract][Full Text] [Related]
3. Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.
Oliveira Santos M; de Carvalho M
Expert Rev Neurother; 2024 Jun; 24(6):549-553. PubMed ID: 38758193
[TBL] [Abstract][Full Text] [Related]
4. Trial of Antisense Oligonucleotide Tofersen for
Miller TM; Cudkowicz ME; Genge A; Shaw PJ; Sobue G; Bucelli RC; Chiò A; Van Damme P; Ludolph AC; Glass JD; Andrews JA; Babu S; Benatar M; McDermott CJ; Cochrane T; Chary S; Chew S; Zhu H; Wu F; Nestorov I; Graham D; Sun P; McNeill M; Fanning L; Ferguson TA; Fradette S;
N Engl J Med; 2022 Sep; 387(12):1099-1110. PubMed ID: 36129998
[TBL] [Abstract][Full Text] [Related]
5. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for
Miller T; Cudkowicz M; Shaw PJ; Andersen PM; Atassi N; Bucelli RC; Genge A; Glass J; Ladha S; Ludolph AL; Maragakis NJ; McDermott CJ; Pestronk A; Ravits J; Salachas F; Trudell R; Van Damme P; Zinman L; Bennett CF; Lane R; Sandrock A; Runz H; Graham D; Houshyar H; McCampbell A; Nestorov I; Chang I; McNeill M; Fanning L; Fradette S; Ferguson TA
N Engl J Med; 2020 Jul; 383(2):109-119. PubMed ID: 32640130
[TBL] [Abstract][Full Text] [Related]
6. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
Benatar M; Wuu J; Andersen PM; Bucelli RC; Andrews JA; Otto M; Farahany NA; Harrington EA; Chen W; Mitchell AA; Ferguson T; Chew S; Gedney L; Oakley S; Heo J; Chary S; Fanning L; Graham D; Sun P; Liu Y; Wong J; Fradette S
Neurotherapeutics; 2022 Jul; 19(4):1248-1258. PubMed ID: 35585374
[TBL] [Abstract][Full Text] [Related]
7. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice.
Meyer T; Schumann P; Weydt P; Petri S; Koc Y; Spittel S; Bernsen S; Günther R; Weishaupt JH; Dreger M; Kolzarek F; Kettemann D; Norden J; Boentert M; Vidovic M; Meisel C; Münch C; Maier A; Körtvélyessy P
Muscle Nerve; 2023 Jun; 67(6):515-521. PubMed ID: 36928619
[TBL] [Abstract][Full Text] [Related]
8. From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of
van Roon-Mom W; Ferguson C; Aartsma-Rus A
Nucleic Acid Ther; 2023 Aug; 33(4):234-237. PubMed ID: 37581487
[No Abstract] [Full Text] [Related]
9. Tofersen: Silver Lining or Hyperbole??
Chawla T; Goyal V
Ann Indian Acad Neurol; 2023; 26(5):638-640. PubMed ID: 38022476
[TBL] [Abstract][Full Text] [Related]
10. Tofersen (Qalsody) for ALS.
Med Lett Drugs Ther; 2023 Jul; 65(1681):113-114. PubMed ID: 37460141
[No Abstract] [Full Text] [Related]
11. CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS).
Bireley JD; Morren JA
Expert Opin Investig Drugs; 2023; 32(8):677-683. PubMed ID: 37642362
[TBL] [Abstract][Full Text] [Related]
12. Myelitis as a side effect of tofersen therapy in SOD1-associated ALS.
Reilich P; Schöberl F; Hiebeler M; Tonon M; Ludolph AC; Senel M
J Neurol; 2024 Apr; 271(4):2114-2118. PubMed ID: 38066205
[No Abstract] [Full Text] [Related]
13. New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022.
Jiang J; Wang Y; Deng M
Front Pharmacol; 2022; 13():1054006. PubMed ID: 36518658
[TBL] [Abstract][Full Text] [Related]
14. A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model.
Post J; Kogel V; Schaffrath A; Lohmann P; Shah NJ; Langen KJ; Willbold D; Willuweit A; Kutzsche J
Molecules; 2021 Mar; 26(6):. PubMed ID: 33805709
[TBL] [Abstract][Full Text] [Related]
15. Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis.
Amporndanai K; Rogers M; Watanabe S; Yamanaka K; O'Neill PM; Hasnain SS
EBioMedicine; 2020 Sep; 59():102980. PubMed ID: 32862101
[TBL] [Abstract][Full Text] [Related]
16. [Familial Amyotrophic Lateral Sclerosis].
Suzuki N; Nishiyama A; Kato M; Warita H; Aoki M
Brain Nerve; 2019 Nov; 71(11):1169-1181. PubMed ID: 31722303
[TBL] [Abstract][Full Text] [Related]
17. Pathological Modification of TDP-43 in Amyotrophic Lateral Sclerosis with SOD1 Mutations.
Jeon GS; Shim YM; Lee DY; Kim JS; Kang M; Ahn SH; Shin JY; Geum D; Hong YH; Sung JJ
Mol Neurobiol; 2019 Mar; 56(3):2007-2021. PubMed ID: 29982983
[TBL] [Abstract][Full Text] [Related]
18. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS).
Abati E; Bresolin N; Comi G; Corti S
Expert Opin Ther Targets; 2020 Apr; 24(4):295-310. PubMed ID: 32125907
[No Abstract] [Full Text] [Related]
19. Overview of current and emerging therapies for amytrophic lateral sclerosis.
Chen JJ
Am J Manag Care; 2020 Aug; 26(9 Suppl):S191-S197. PubMed ID: 32840332
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
